Srdan Verstovsek, MD, PhD | Authors

Articles

Behind the FDA Approval: Pemigatinib for R/R Myeloid/Lymphoid Neoplasms

August 30, 2022

In the interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the FDA approval of pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. He also discussed the FIGHT-203 trial, and possibilities for pemigatinib in the future.